CC BY-NC-ND 4.0 · J Lab Physicians 2009; 1(02): 053-055
DOI: 10.4103/0974-2727.59699
Original Article

Emergence of Nonalbicans Candida in Neonatal Septicemia and Antifungal Susceptibility: Experience from a Tertiary Care Center

Nidhi Goel
Department of Microbiology, Pt. B.D.S. PGIMS, Rohtak, India
,
Prabhat K Ranjan
Department of Microbiology, Pt. B.D.S. PGIMS, Rohtak, India
,
Ritu Aggarwal
Department of Microbiology, Pt. B.D.S. PGIMS, Rohtak, India
,
Uma Chaudhary
Department of Microbiology, Pt. B.D.S. PGIMS, Rohtak, India
,
Nanda Sanjeev
Department of Pediatrics, Pt. B.D.S. PGIMS, Rohtak, India
› Author Affiliations
Source of Support: Nil

ABSTRACT

Aims: To know the distribution and antifungal susceptibility pattern of Candida species in neonatal septicemia cases.

Materials and Methods: In a prospective analysis blood samples from 825 clinically suspected cases of neonatal septicemia, collected aseptically, were cultured to look for the role of Candida spp. in septicemia. Candida isolates were speciated by germ tube test, Hi-CHROME agar, sugar fermentation, and sugar assimilation tests using standard protocol. All the Candida isolates were tested for antifungal susceptibility to fluconazole by the Disk Diffusion (DD) method and broth micro dilution-minimum inhibitory concentration (BMD-MIC) method using NCCLS guidelines.

Results: Isolation rate of Candida from neonatal septicemia cases was 8.1%. Most common isolate was C. tropicalis (61.19%), followed by C. albicans (19.40%), C. glabrata (11.94%), C. parapsilosis (5.97%) and C. guillermondii (1.49%). Low birth weight and previous antibiotic prophylaxis was found in 100% cases. Crude mortality rate was 50.1%. By DD method, 95.53% of the Candida isolates were sensitive to fluconazole. A discrepancy between DD method and BMD-MIC method was noted in 4.47% strains. One isolates each of C. tropicalis, C. albicans, and C. glabrata showed discrepancy.

Conclusion: Nonalbicans Candida has emerged as an important cause of neonatal septicemia. Routine susceptibility testing of Candida isolates by DD method should be confirmed by BMD-MIC method. Fluconazole can be used as empirical therapy for neonatal candidemia at our center.



Publication History

Publication Date:
29 January 2020 (online)

© 2009.

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 
  • REFERENCES

  • 1 Baradkar VP, Mathur M, Kumar S, Rathi M. Candida glabrata emerging pathogen in neonatal sepsis. Ann Trop Med Public Health 2008;1:5-8.
  • 2 Agarwal J, Bansal S, Mailk GK, Jain A. Trends in neonatal septicemia: Emergence of non-albican Candida. Indian Pediatr 2004;41:712-5.
  • 3 Hobson RP The global epidemiology of invasive Candida infections: Is the tide turning? J Hosp Infect 2003;20:159-68.
  • 4 Chander J. Candidiasis. A text book of medical mycology. 3 rd ed. New Delhi: Mehta Publishers; 2009. p. 266-90.
  • 5 National Committee for Clinical Laboratory Standards. Methods for antifungal disk diffusion susceptibility testing yeast: Approved guideline M-44A. Wayne, PA: NCCLS; 2004.
  • 6 National Committee for Clinical Laboratory Standards. Reference method for broth dilution testing of yeast approved standard. 2 nd ed. M27-A2.Wayne, PA: NCCLS; 2002.
  • 7 Chakrabarti A, Shivaprakash MR. Microbiology of systemic fungal infection. J Postgrad Med 2005;51:16-20.
  • 8 Xess I, Jain N, Hasan F, Mandal P, Banerjee U. Epidemiology of candidemia in a tertiary care centre of North India: 5-year study. Infection 2007;35:256-9.
  • 9 Baradkar VP, Mathur M, Kumar S, Rathi M. Candida glabrata emerging pathogen in neonatal sepsis. Ann Trop Med Pub Health 2008;1:5-8.
  • 10 Narain, Shastri JS, Mathur M, Mehta PR. Neonatal systemic candidiasis in a tertiary care hospital. Indian J Med Microbiol 2003;21:56-8.